Sana Biotechnology Inc., which launched in January, has struck a license agreement with Harvard University's Office of Technology Development to produce hypoimmunogenic stem cells that can be transplanted into patients and not trigger immune rejection. Sana, a regenerative medicine company founded by former Juno Therapeutics Inc. execs Hans Bishop and Steve Harr, focuses on creating engineered cells as medicine for patients.